Get started
SHLF buying opportunity?SHLF made a ridiculous breakout at the beginning of this week. Since then has come down pretty hard as well. So looking for potential support and buying opportunities. After the recent bottom formation the break out occurred after mounting the 3.80-3.93 resistance area. This could now provide support. Furthermore, if SHLF was to retest this level it would also touch on the upward trendline (blue) that has been established since the bottom, providing further support. And finally also note the gap that's still there at 3.70. On the ichimoku cloud front: - We are above the 4h cloud and the top of the cloud is currently sitting at the same level as the horizontal support area. - We are below the daily cloud, and got rejected after trying to enter at the beginning of the week. So let's see if we can find support to retry conquering the cloud on the daily.
OSL:SHLF
by duco1
Norwegian airlines, Company evaluation and long-entry strategy ABOUT - Low cost airline company that offer nice and comfortable, cheap flights to (especially) Europe and Worldwide destinations. - Adapting Bitcoin as accepted payment from August. MANAGEMENT - One of two major airlines in Norway. - Been taking a substantial beating during the Coronavirus crisis, risking bankruptcy. - Change of management last year. Previous management took a lot of irresponsible expansion risks. Current management is more responsible and have a lot of experience. Continuous restructuring since takeover. - Company saved through converting bonds recently, lowering the debt/equity ratio although the ratio is still high. Converting-action had the company meet loan requirements set out by the Norwegian government. Now set to survive and hopefully thrive as boarders open. BALANCE SHEET - Total Assets - Total Debt = 20.965 B - Market Cap = 11.542 B - Price to Book ratio = 0.1535 (in comparison - other airlines: SAS = 1.0348, LHA = 0.4604, UAL = 0.6294, DAL = 1.0739) - Price to Sales ratio = 0.118 (in comparison - other airlines: SAS = 0.0919, LHA = 0.1276, UAL = 0.1736, DAL = 0.3565) - Debt to Equity ratio = 14.8798 (in comparison - other airlines: SAS = - 24.6038 LHA = 0.9780 UAL = 2.4877 DAL = 1.6054) - NOTE: Total debt of approximately 10.0 B has been converted from bond debt to stock shares and is reflected in the Market Cap noted above, however it is not reflected in the Total Debt since the conversion will not be visible until the 2020 Annual Report. RISK FACTORS - Bankruptcy a lot less likely, but may still be possible if the crisis stretches out for a while. - Total Assets value probably does not reflect actual value if many airlines go bankrupt at the same time since demand for assets will fall, especially if travel restrictions continue. - Price is volatile with a one year beta of 2.0667. - Company is highly leveraged which obviously makes this investment risky, but this will likely be reflected in the profits. Norwegian Airlines reached its all-time-high back in 2015 with a price of NOK 220 which means that the current value represent a shave-off of 98.4 % since then. - Human psychology of Norwegian small scale (private) investors represent a significant contribution to price fluctuations. VOLUME - Recent PUMP-UP in volume on the daily (idea post) and the monthly chart (below) signals a massive ramp up by institutional investors. As you can see, the monthly volume is HUGE in the context of volume history since the start in 2004. We have never seen such wild volume. CAUTION: wait and see if this is a PUMP-UP-SIGNAL or a WARNING-SIGNAL. Monthly volume: TRADING STRATEGY - The price has been falling on this volume, although not significantly. In comparison, the price fell by approximately 88.1 % due to the coronavirus crash. - Wait and see what happens with daily, weekly and perhaps monthly indicators. If parabolic SAR dots start supporting an upwards trend and we see a shift in configuration of the Exponential Moving Average ribbon, it will be a good time to get into a long position and we can consider the recent volume pump up to reflect a charge signal. - Get out if SAR and EMA-ribbon switch direction in momentum, also pay attention to the resistance- and fibonacci-levels. Macro resistance-levels and -zones to watch out for: Macro fibonacci-levels: I you have any questions, feel free to ask me in the comments. Cheers, Navigating Shifting Landscapes
OSL:NASLong
by Navigating_Shifting_Landscapes
15
BGBIO - an intelligent bet on covidBGBIO is a biotech company with focus on cancer treatment. Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident. BGBIO is presenting news on their cancer treatment 25th of june. They are currently first in line to do a free test in ACCORD - the British rushed testing setup for COVID-19 Before news I expect the share to keep bouncing back and forth between the buy zone (established from a large public offering at 37,5 - 50 MUSD) to the sell zone (as seen on TA). BLUE ARROWS Any movements outside this zone is unlikely before we get more news. If we do get positive news as to treatment going well, the share could very quickly get an insane pricing (2-3x current price). However, as we have seen from a lot of other companies lately, just starting or finishing test phases without failing = price increase. I expect such a movement sometime the next two weeks. The CEO has indicated he will let the market know asap when the study starts and I expect that announcement to quickly bounce the price to ~50 NOK before it retraces to the current sell zone. When this happens it will turn into the new buy zone. 1) Go long with a position, you can collect a probable 25% at 50 NOK within 2-4 weeks 2) Play the swing trade between 37-39 and 42-44 with some of your position in the meantime ____________________ 3) If for some reason the first phase should not go as planned and their drug will not be suitable for covid, the drug is still very well touted for cancer and has the next potential boost at june 25th
OSL:BGBIOLong
by ssholtskog
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote: "Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86. Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely." Source: www.research-tree.com
OSL:BGBIOLong
by savepiginvest